Biothera Phase II Lung Cancer Trials Achieve Stage 1 Goals

Published: Apr 19, 2011

EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today that its second Phase II non-small cell lung cancer trial, evaluating Imprime PGG® in combination with bevacizumab (Avastin®) and two chemotherapeutic agents, has achieved its stage 1 endpoint and has begun enrolling patients for stage 2 of the study.

Back to news